2023 Q1 Form 10-K Financial Statement

#000089843223000193 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $278.1K $10.00K $35.39K
YoY Change 969.77%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $278.1K $10.00K $35.39K
YoY Change 969.77%
Operating Profit -$35.39K
YoY Change 969.77%
Interest Expense $420.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $140.0K -$10.00K -$40.00K
YoY Change
Income Tax $29.32K
% Of Pretax Income 20.94%
Net Earnings $110.3K -$10.00K -$35.39K
YoY Change -87643.65% 969.77%
Net Earnings / Revenue
Basic Earnings Per Share $0.02 -$0.01
Diluted Earnings Per Share $0.02 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 9.055M shares 1.500M
Diluted Shares Outstanding 5.231M 1.500M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $350.0K $120.0K $120.0K
YoY Change
Cash & Equivalents $348.8K $124.5K
Short-Term Investments
Other Short-Term Assets $80.00K
YoY Change
Inventory
Prepaid Expenses $81.07K
Receivables
Other Receivables
Total Short-Term Assets $429.9K $124.5K $120.0K
YoY Change 2517.22%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $70.63M
YoY Change
Other Assets $0.00 $1.100M $1.100M
YoY Change 57.14%
Total Long-Term Assets $70.63M $1.101M $1.110M
YoY Change 57.26% 56.34%
TOTAL ASSETS
Total Short-Term Assets $429.9K $124.5K $120.0K
Total Long-Term Assets $70.63M $1.101M $1.110M
Total Assets $71.06M $1.226M $1.230M
YoY Change 73.86% 73.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $390.0K $30.00K $30.00K
YoY Change
Accrued Expenses $0.00 $10.00K $10.00K
YoY Change -96.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $1.200M $1.200M
YoY Change 200.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $403.4K $1.263M $1.260M
YoY Change 78.64% 77.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $403.4K $1.263M $1.260M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.473M $1.263M $1.260M
YoY Change 78.64% 77.46%
SHAREHOLDERS EQUITY
Retained Earnings -$1.830M -$62.51K
YoY Change 130.49%
Common Stock $216.00 $173.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.830M -$37.51K -$40.00K
YoY Change
Total Liabilities & Shareholders Equity $71.06M $1.226M $1.230M
YoY Change 73.86% 73.24%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $110.3K -$10.00K -$35.39K
YoY Change -87643.65% 969.77%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$48.43K $0.00 -$4.235K
YoY Change 38333.33% 818.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$70.21M
YoY Change
Cash From Investing Activities -$70.21M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $70.48M 50.00K $124.0K
YoY Change 599170.7% -600.0% -315.86%
NET CHANGE
Cash From Operating Activities -$48.43K 0.000 -$4.235K
Cash From Investing Activities -$70.21M
Cash From Financing Activities $70.48M 50.00K $124.0K
Net Change In Cash $224.3K 50.00K $119.7K
YoY Change 1827.81% -600.0% -306.83%
FREE CASH FLOW
Cash From Operating Activities -$48.43K $0.00 -$4.235K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity Registrant Name
EntityRegistrantName
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity File Number
EntityFileNumber
001-41390
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-5052822
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
10900 NE 4th Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2300
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Bellevue
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98004
CY2022 dei City Area Code
CityAreaCode
425
CY2022 dei Local Phone Number
LocalPhoneNumber
635-7700
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 dei Entity Public Float
EntityPublicFloat
0 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9055000 shares
CY2022 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2022 dei Auditor Location
AuditorLocation
New York, New York
CY2022 dei Auditor Firm
AuditorFirmId
100
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124501 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4757 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
124501 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
4757 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1101353 usd
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
700330 usd
CY2022Q4 us-gaap Assets
Assets
1225854 usd
CY2021Q4 us-gaap Assets
Assets
705087 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2847 usd
CY2022Q4 blac Accrued Offering Costs Current
AccruedOfferingCostsCurrent
12362 usd
CY2021Q4 blac Accrued Offering Costs Current
AccruedOfferingCostsCurrent
294360 usd
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1200000 usd
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
400000 usd
CY2022Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
17000 usd
CY2021Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
10000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1263362 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
707207 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1263362 usd
CY2021Q4 us-gaap Liabilities
Liabilities
707207 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1725000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1725000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1725000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1725000 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
173 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
173 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24827 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24827 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62508 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27120 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-37508 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2120 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1225854 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
705087 usd
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35388 usd
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3308 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-35388 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-3308 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35388 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-3308 usd
CY2022 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1500000 shares
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1500000 shares
CY2022 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1188 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-3308 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2120 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35388 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-37508 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-35388 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-3308 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
31153 usd
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2847 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4235 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-461 usd
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
683021 usd
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
167435 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
800000 usd
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
100000 usd
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
10000 usd
CY2022 us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
17000 usd
CY2021 us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
10000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
123979 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-57435 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
119744 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-57896 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4757 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62653 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124501 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4757 usd
CY2022 blac Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
12362 usd
CY2021 blac Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
294360 usd
CY2022Q4 blac Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1 pure
CY2023Q1 us-gaap Share Price
SharePrice
10
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
9000000 usd
CY2022 blac Percentage Of Trust Account Required For Business Combination
PercentageOfTrustAccountRequiredForBusinessCombination
0.80 pure
CY2022 blac Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination
ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination
0.50 pure
CY2022Q4 us-gaap Common Stock Held In Trust
CommonStockHeldInTrust
70207500000000 usd
CY2022Q4 blac Net Tangible Assets
NetTangibleAssets
5000001 usd
CY2022 blac Redemption Limit Percentage
RedemptionLimitPercentage
0.15 pure
CY2022 blac Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1 pure
CY2022 blac Period To Consummate Business Combination
PeriodToConsummateBusinessCombination
P9M
CY2022 blac Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
100000 usd
CY2022Q4 us-gaap Cash
Cash
124501 usd
CY2022Q4 us-gaap Debt Current
DebtCurrent
1138861 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: bold;">Use of Estimates</div><div style="font-weight: normal;"><br/> </div><div style="text-align: justify; text-indent: 36pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: normal;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements and the reported amounts of expenses during the reporting period.</div><div style="font-weight: normal;"><br/> </div><div style="text-align: justify; text-indent: 36pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: normal;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</div><div style="font-weight: normal;"><br/> </div>
CY2022Q4 us-gaap Cash
Cash
124501 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: bold;">Concentration of Credit Risk</div><div style="font-weight: normal;"><br/> </div><div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32); font-weight: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of</span><span style="font-weight: normal; font-size: 10pt;"> <span style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);">$250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</span></span></div><div style="font-weight: normal;"><br/> </div>
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
7500 usd
CY2022Q4 blac Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
2 pure
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0 usd
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001840425

Files In Submission

Name View Source Status
0000898432-23-000193-index-headers.html Edgar Link pending
0000898432-23-000193-index.html Edgar Link pending
0000898432-23-000193.txt Edgar Link pending
0000898432-23-000193-xbrl.zip Edgar Link pending
blac-20221231.htm Edgar Link pending
blac-20221231.xsd Edgar Link pending
exh31-1.htm Edgar Link pending
exh31-2.htm Edgar Link pending
exh32-1.htm Edgar Link pending
exh32-2.htm Edgar Link pending
exh4-7.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
blac-20221231_cal.xml Edgar Link unprocessable
blac-20221231_def.xml Edgar Link unprocessable
blac-20221231_lab.xml Edgar Link unprocessable
blac-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
blac-20221231_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending